A 12 Week Open Label, Parallel Group, Comparative, Multicentric Phase III Study to Assess Efficacy and Safety of Metered Dose Buccal Insulin Spray versus Rapid Insulin s.c. on subjects with type II Diabetes who are inadequately controlled i.e. HbA1C 6.5 to 8.5 while on Oral Anti- Diabetic Agents - BUCLAR

Trial Profile

A 12 Week Open Label, Parallel Group, Comparative, Multicentric Phase III Study to Assess Efficacy and Safety of Metered Dose Buccal Insulin Spray versus Rapid Insulin s.c. on subjects with type II Diabetes who are inadequately controlled i.e. HbA1C 6.5 to 8.5 while on Oral Anti- Diabetic Agents - BUCLAR

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Insulin (Primary) ; Insulin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Jul 2013 Status changed from active, no longer recruiting to completed.
    • 10 Jul 2013 Results published in Generex Biotechnology Corporation Media Release.
    • 12 Nov 2012 New source identified and integrated (Clinical Trials Registry - India CTRI2012-09-003033).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top